Conduit Pharmaceuticals Quote - CDT

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.0709

Bid

0.0655

Ask

0.0715

Volume

19,962,479

0.0619 Day's Range 0.0758

0.0621 52 Week Range 6.10

Market Cap

7.292M

Previous Close

0.0656

Open

0.0619

Last Trade

0.068

Last Trade Time

Financial Volume

US$ 1,374,568

VWAP

0.068858

Average Volume (3m)

26,681,405

Shares Outstanding

102,847,973

Dividend Yield

PE Ratio

-286.08

Earnings Per Share (EPS)

-0.06

Revenue

Net Profit

-6.06M

Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmun... Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto's Thyroiditis. The Company's asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto's Thyroiditis (HT) and Graves' disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto's Thyroiditis and Graves' disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI). Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.conduitpharma.com

Headquarters

Wilmington, Delaware, USA

Founded

Conduit Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CDT. The last closing price for Conduit Pharmaceuticals was US$0.07. Over the last year, Conduit Pharmaceuticals shares have traded in a share price range of US$ 0.0621 to US$ 6.10.

Conduit Pharmaceuticals currently has 102,847,973 shares outstanding. The market capitalization of Conduit Pharmaceuticals is US$6.75 million. Conduit Pharmaceuticals has a price to earnings ratio (PE ratio) of -286.08.

Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and...

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced...

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital...

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial...

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright...

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656AZD1656, a HK-4...

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.011201	-13.6429519738	0.082101	0.0872	0.0621	14433883	0.07466572	CS
4	-0.0284	-28.6002014099	0.0993	0.1189	0.0621	15733208	0.08615868	CS
12	-0.0553	-43.8193343899	0.1262	0.1579	0.0621	26681405	0.10556276	CS
26	-1.6191	-95.8047337278	1.69	1.805	0.0621	18714813	0.13323266	CS
52	-4.4791	-98.4417582418	4.55	6.1	0.0621	9526670	0.14002336	CS
156	-12.5291	-99.4373015873	12.6	12.89	0.0621	7769497	0.1742911	CS
260	-12.5291	-99.4373015873	12.6	12.89	0.0621	7769497	0.1742911	CS

CDT - Frequently Asked Questions (FAQ)

What is the current Conduit Pharmaceuticals share price?

The current share price of Conduit Pharmaceuticals is US$ 0.0709

How many Conduit Pharmaceuticals shares are in issue?

Conduit Pharmaceuticals has 102,847,973 shares in issue

What is the market cap of Conduit Pharmaceuticals?

The market capitalisation of Conduit Pharmaceuticals is USD 6.75M

What is the 1 year trading range for Conduit Pharmaceuticals share price?

Conduit Pharmaceuticals has traded in the range of US$ 0.0621 to US$ 6.10 during the past year

What is the PE ratio of Conduit Pharmaceuticals?

The price to earnings ratio of Conduit Pharmaceuticals is -286.08

What is the reporting currency for Conduit Pharmaceuticals?

Conduit Pharmaceuticals reports financial results in USD

What is the latest annual profit for Conduit Pharmaceuticals?

The latest annual profit of Conduit Pharmaceuticals is USD -6.06M

What is the registered address of Conduit Pharmaceuticals?

The registered address for Conduit Pharmaceuticals is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Conduit Pharmaceuticals website address?

The website address for Conduit Pharmaceuticals is www.conduitpharma.com

Which industry sector does Conduit Pharmaceuticals operate in?

Conduit Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MYSZMy Size Inc	US$ 4.2001 (211.12%)	121.03M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	78.06M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	34M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.94k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	121.95M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.91M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.75M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.94M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	9.27M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	6.25M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.32M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	305.1M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	292.16M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	287.21M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	277.63M